{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:59:48Z","timestamp":1767135588468,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":63,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd007778","type":"reference-entry","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T15:23:45Z","timestamp":1239809025000},"source":"Crossref","is-referenced-by-count":20,"title":["Chlorpromazine dose for people with schizophrenia"],"prefix":"10.1002","author":[{"given":"Xiaomeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"De Haan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,15]]},"reference":[{"issue":"2-3","key":"10.1002\/14651858.CD007778-BIB1|cit1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000117539","article-title":"Alpha-methyldopa-chlorpromazine combination in schizophrenic patients","volume":"2","author":"Chouinard","year":"1976","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD007778-BIB2|cit2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cpt1970116883","article-title":"The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients","volume":"11","author":"Clark","year":"1970","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD007778-BIB3|cit3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF00412672","article-title":"Chlorpromazine in chronic schizophrenia: behavioral dose-response relationships","volume":"18","author":"Clark","year":"1970","journal-title":"Psychopharmacologia"},{"issue":"4","key":"10.1002\/14651858.CD007778-BIB4|cit4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/archpsyc.1972.01750280047009","article-title":"Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships","volume":"27","author":"Clark","year":"1972","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD007778-BIB5|cit5","first-page":"251","article-title":"EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking","volume":"4","author":"Serafetinides","year":"1972","journal-title":"Biological Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD007778-BIB6|cit6","first-page":"983","article-title":"A 12 year follow up study of chronic schizophrenics.","volume":"33","author":"Gardos","year":"1982","journal-title":"Hospital and Community Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD007778-BIB8|cit7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archpsyc.1968.01740040098013","article-title":"High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group","volume":"18","author":"Prien","year":"1968","journal-title":"Archives of General Psychiatry"},{"issue":"523","key":"10.1002\/14651858.CD007778-BIB7|cit8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1192\/bjp.115.523.679","article-title":"Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication","volume":"115","author":"Prien","year":"1968","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD007778-BIB9|cit9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/archpsyc.1970.01750050080011","article-title":"Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study","volume":"23","author":"Prien","year":"1970","journal-title":"Archives of General Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD007778-BIB10|cit10","first-page":"739","article-title":"Indications for high dose chlorpromazine therapy in chronic schizophrenia","volume":"31","author":"Prien","year":"1970","journal-title":"Diseases of the Nervous System"},{"issue":"2","key":"10.1002\/14651858.CD007778-BIB11|cit11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0447.1978.tb06929.x","article-title":"Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine","volume":"58","author":"Wode-Helgodt","year":"1978","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD007778-BIB12|cit12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1192\/bjp.128.5.451","article-title":"A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients","volume":"128","author":"Andrews","year":"1976","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD007778-BIB13|cit13","first-page":"109","article-title":"Serum chlorpromazine and prolactin levels in paranoid schizophrenic patients and clinical response. Regional Symposium of the World","volume":"2","author":"Bartko","year":"1988","journal-title":"European Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007778-BIB14|cit14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00592679","article-title":"Chlorpromazine in chronic schizophrenic women: I. Experimental design and effects at maximum point of treatment","volume":"2","author":"Clark","year":"1961","journal-title":"Psychopharmacologia"},{"key":"10.1002\/14651858.CD007778-BIB16|cit15","first-page":"191","article-title":"A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients","volume-title":"Pharmacokinetics of psychoactive drugs","author":"Clark","year":"1976"},{"issue":"3","key":"10.1002\/14651858.CD007778-BIB15|cit16","first-page":"43","article-title":"Chlorpromazine kinetics and clinical response","volume":"14","author":"Clark","year":"1978","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD007778-BIB17|cit17","first-page":"209","article-title":"Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs","volume":"9","author":"Crane","year":"1968","journal-title":"Agressologie"},{"key":"10.1002\/14651858.CD007778-BIB18|cit18","article-title":"Antipsychotic drugs. I. chlorpromazine: Pharmacokinetics, plasma levels and clinical response","volume-title":"Plasma levels of psychotropic drugs and clinical response","author":"Curry","year":"1978"},{"key":"10.1002\/14651858.CD007778-BIB19|cit19","first-page":"343","article-title":"Metabolism and kinetics of chlorpromazine in relation to effect","volume-title":"Antipsychotic drugs: pharmacodynamics and pharmacokinetics","author":"Curry","year":"1976"},{"key":"10.1002\/14651858.CD007778-BIB20|cit20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0006-3223(97)00452-6","article-title":"The effects of chlorpromazine and lorazepam on abnormal antisaccade and no-saccade distractibility","volume":"44","author":"Green","year":"1998","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD007778-BIB21|cit21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s002130050111","article-title":"A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam","volume":"128","author":"Green","year":"1996","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD007778-BIB22|cit22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-0447.1982.tb04504.x","article-title":"ECT-chlorpromazine combination versus chlorpromazine alone in acutely schizophrenic patients","volume":"66","author":"Janakiramaiah","year":"1982","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD007778-BIB23|cit23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF01575453","article-title":"Comparison of low and high dosage procedures in chlorpromazine therapy","volume":"33","author":"Schiele","year":"1959","journal-title":"Psychiatric quarterly"},{"issue":"2","key":"10.1002\/14651858.CD007778-BIB24|cit24","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000284.pub2","article-title":"Chlorpromazine versus placebo for schizophrenia","author":"Adams","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007778-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007778-BIB26|cit26","volume-title":"Statistical methods in medical research","author":"Armitage","year":"1971"},{"key":"10.1002\/14651858.CD007778-BIB27|cit27","first-page":"7991","article-title":"Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses","volume":"45","author":"RJ","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD007778-BIB28|cit28","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007778-BIB29|cit29","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD007778-BIB30|cit30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S003329170002729X","article-title":"Antipsychotic drugs: is more worse? A meta analysis of the published randomised control trials","volume":"24","author":"P","year":"1994","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD007778-BIB31|cit31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","article-title":"Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine or normetanephrine in mouse brain","volume":"20","author":"Carlsson","year":"1963","journal-title":"Acta Pharmacologica et Toxicologica"},{"issue":"10","key":"10.1002\/14651858.CD007778-BIB32|cit32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"12 Suppl 21","key":"10.1002\/14651858.CD007778-BIB33|cit33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1017\/S1092852900015959","article-title":"Acute and long-term adverse effects of antipsychotics","volume":"12","author":"Correll","year":"2007","journal-title":"CNS spectrums"},{"key":"10.1002\/14651858.CD007778-BIB34|cit34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0022-3956(74)90071-5","article-title":"Dose equivalence of the antipsychotic drugs","volume":"11","author":"David","year":"1974","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD007778-BIB35|cit35","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4613-4042-3_4","article-title":"Neuroleptics: clinical use in psychiatry","volume-title":"Handbook of psychopharmacology","author":"Davis","year":"1978"},{"key":"10.1002\/14651858.CD007778-BIB36|cit36","first-page":"1591","article-title":"Antipsychotic drugs","volume-title":"Comprehensive textbook of psychiatry","author":"JM","year":"1989"},{"key":"10.1002\/14651858.CD007778-BIB37|cit37","series-title":"Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa","article-title":"Issues in the selection for meta-analyses of binary data","author":"Deeks","year":"2000"},{"key":"10.1002\/14651858.CD007778-BIB38|cit38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD007778-BIB39|cit39","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007778-BIB40|cit40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD007778-BIB41|cit41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiol"},{"key":"10.1002\/14651858.CD007778-BIB42|cit42","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale. A procedure to measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD007778-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: a systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007778-BIB44|cit44","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007778-BIB45|cit45","first-page":"217","volume-title":"Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD007778-BIB46|cit46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007778-BIB47|cit47","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for systematic reviews of interventions 5.0.1 [updated September 2008]","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD007778-BIB48|cit48","doi-asserted-by":"crossref","DOI":"10.1002\/9780470987353","volume-title":"Schizophrenia","author":"Hirsch","year":"2003"},{"key":"10.1002\/14651858.CD007778-BIB49|cit49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007778-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD007778-BIB51|cit51","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/j.1552-4604.1988.tb03117.x","article-title":"Does chlorpromazine produce cardiac arrhythmia via the central nervous system?","volume":"28","author":"Lipka","year":"1988","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD007778-BIB52|cit52","volume-title":"Inpatient multidimensional psychiatric scale manual","author":"Lorr","year":"1966"},{"key":"10.1002\/14651858.CD007778-BIB53|cit53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007778-BIB54|cit54","unstructured":"Statistics on Mental Health. Factsheet Mental Health Foundation 2003"},{"key":"10.1002\/14651858.CD007778-BIB55|cit55","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological reports"},{"key":"10.1002\/14651858.CD007778-BIB56|cit56","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"issue":"1","key":"10.1002\/14651858.CD007778-BIB57|cit57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","journal-title":"Canadian journal of psychiatry"},{"key":"10.1002\/14651858.CD007778-BIB58|cit58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavacia"},{"issue":"5","key":"10.1002\/14651858.CD007778-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"11","key":"10.1002\/14651858.CD007778-BIB60|cit60","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0006-3223(01)01252-5","article-title":"Prefrontal neurons and the genetics of schizophrenia","volume":"50","author":"Weinberger","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD007778-BIB61|cit61","unstructured":"WHO The world health report 2001 mental health: new understanding, new hope 2001"},{"key":"10.1002\/14651858.CD007778-BIB62|cit62","unstructured":"WHO model list of essential medicines World Health Organisation"},{"key":"10.1002\/14651858.CD007778-BIB63|cit63","series-title":"Proceedings of the15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo","first-page":"85","article-title":"The Leeds Outcomes Stakeholders Survey (LOSS) Study","author":"Xia","year":"2007"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007778.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T00:00:00Z","timestamp":1492041600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T16:57:10Z","timestamp":1684947430000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007778"}},"subtitle":[],"editor":[{"given":"Xiaomeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2009,4,15]]},"references-count":63,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007778","relation":{},"subject":[],"published":{"date-parts":[[2009,4,15]]}}}